Healthy volunteers help compare new allergy drug to proven treatment
NCT ID NCT07502534
First seen Apr 04, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study tests a new drug called IBI3027 to see if it behaves the same as an approved drug, Dupilumab, in healthy Chinese men aged 18-45. Participants receive a single injection and are monitored for 56 days. The goal is to compare drug levels and safety, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qingdao University Affiliated Hospital
Qingdao, Shandong, Shandong Province, China
Conditions
Explore the condition pages connected to this study.